Compare Edwards Lifesciences Corporation Common Stock (EW) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edwards Lifesciences Corporation Common Stock vs Synopsys, Inc. — how do they compare? Edwards Lifesciences Corporation Common Stock trades at $84.25 (market cap $49.44B), while Synopsys, Inc. trades at $501.02 (market cap $96.33B). The key difference: Synopsys, Inc. is the larger of the two by market cap, and Synopsys, Inc. is trading nearer its 52-week high, Edwards Lifesciences Corporation Common Stock nearer its low. Which is the better fit depends on your goals.
| EW | SNPS | |
|---|---|---|
Market Cap | $49.44B | $96.33B |
Volume | 3,508,027 | 1,631,837 |
Sector | Health | Technology |
52-Week High | $95.18 | $534.56 |
52-Week Low | $72.65 | $367.70 |
Enterprise Value | $45.90B | $103.56B |
Typical Hold Time | — | 71 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Synopsys (SNPS) trades at $497.75, down 1.47% on the day but remains near recent highs following strong quarterly earnings beats and bullish investor sentiment driven by AI partnerships. The stock shows a bullish technical trend with moving averages supporting upside, while RSI levels indicate overbought conditions. Recent news highlights multi-year agreements with OpenAI and Amazon Web Services, fueling growth expectations beyond traditional EDA markets.
The outlook is positive with a consensus price target of $572.54, reflecting 15% upside potential, though high valuation multiples (P/E of 87.73) and integration risks from the Ansys acquisition warrant caution. Revenue growth is projected to accelerate, supported by AI-driven demand, but margin compression and competitive pressures pose medium-term risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Edwards Lifesciences Corporation Common Stock
Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
